Chardan analyst Keay Nakae initiates coverage on CAMP4 Therapeutics Corp (NASDAQ: CAMP) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage